Member Info for Chelsea11

Great timing for anyone prepared to allocate some / all of their 25/26 ISA allowance here.

Lock and load.

Same here TF. Highlighting an insulting comment being an example, when I’m being asked to “give it a break”.

Take it easy.

TF - bout a week or so back, same poster was calling you my “appointed bot” during A conversation about the merits of AI. Perhaps you missed that insult to yourself.

Ruck - perfectly reasonable to call out plagiarism in my view.

Cleaner - that link was posted by JB1 just a few days ago. You absolutely know that because you commented on it. Should you not at least acknowledge you are re-posting someone else’s legwork?

Private James Frazer will be along in a minute.

Just $1M for exclusive rights over Scancell's wider antibody platform? I hope not!

Thanks for coming back with clarity around your thoughts JB1.

Sorry JB1 but I don’t see any relevance to Scancell from the Oxford Bio / Roche deal?

The update on SC129, out-licensed to Genmab in 2022, continues on track towards clinical development with further milestones anticipated, according to the Jan Interims.

Depends which statistics you read & believe (as always) but New Zealand is possibly top of the Melanoma death charts.

And that is interesting given that L’Huillier’s PHD came from the University of Auckland (as well as an MBA) and Melanoma research takes place there.

Of course there is a lower population pool compared to Australia but wouldn’t rule out as a contender with the L’Huillier connection.

HAGW

Well done Trotsky. Good to see you recognised yourself from my description 😂

“ Continued momentum for Oxford Metrics' smart manufacturing division”

Any comment from the resident Smart Manufacturing critic?

Super research JB1.

Last time there was no RNS in a calendar month was Aug 24 and that was the only month last year without seeing one.

Therefore based on that recent history, the odds are favourable for receiving something this month, especially with all the known conference attendance.

Trial timelines have of course been clearly articulated but a fair chance news outside of that will arrive inside the next couple of weeks.

Dracula - perhaps tomorrow, try getting out the other side of your coffin 😂

To layer on top of that, as the organisation has grown, more folk with a proven commercial nous have joined. Reasonable to believe then that conversations at those conferences, whether planned or unplanned, have had a greater commercial bias than in the past. So a double bubble of more exposure harnessed to convos that may result in shareholder value.

HAGW

Cleaner - I prefer to keep the conversation honest. Seems you don’t, as you accuse me of appointing a Bot, which is of course yet more nonsense and at the same time insulting to another poster here.

Now you’re posting a link to an article approaching 3 years old about the structure of the protein universe 😂

Cleaner - you clearly have no understanding of what you are posting. Yes, AI will be able to crunch huge amounts of complex data. This will have obvious benefits across many industries.

However that is totally different to asking Bob on the web, whether one drug is, or will be, better than another.

Cleaner - you’ve posted that directly in response to my post agreeing with the opinions of both BOJO and also Bermuda.

Nonsense.

To be fair Bojo, it looks to me like Berm was just offering up some additional clarification & perspective on another posters point of view.

However I agree with you. Ancient history won’t help us here.

Nor in my opinion, will a chat bot.

Please - not another Genmab fetish 🤪

AI is just spewing out information from sources it can find. Whether that is correct, complete or fully up to date, it doesn’t care.